Poor
Needs Revision
Patient Risk:
Moderate
Summary
Many claims are either unsupported or contradict the provided FDA label text. Several patient-safety relevant statements (pancreatitis risk determination, swallowing/capsule handling, pregnancy risk framing, and pediatric effectiveness) conflict with the label, substantially reducing alignment.
Category Scores
Accurate Statements
Vascepa is a branded medication.
The generic name of Vascepa is icosapent ethyl.
Section 1 INDICATIONS AND USAGE header: 'VASCEPA (icosapent ethyl)'.
Vascepa is a prescription medication used to treat high triglycerides.
Section 1 INDICATIONS AND USAGE: indicated as adjunct to statin therapy to reduce cardiovascular risk in adults with elevated triglycerides and as adjunct to diet to reduce TG levels in adults with severe hypertriglyceridemia.
Vascepa is used to treat severe hypertriglyceridemia.
Section 1 INDICATIONS AND USAGE (second bullet).
Unsupported Statements
Vascepa assistance programs provide financial assistance, discounts, and other benefits to eligible patients.
No prescribing-information support provided in the supplied label sections for assistance program details.
Vascepa assistance programs are designed to make Vascepa more accessible and affordable for patients who need it.
No prescribing-information support provided in the supplied label sections.
To qualify for Vascepa assistance, patients must meet eligibility criteria that typically include income requirements.
No prescribing-information support provided in the supplied label sections.
Income requirements for Vascepa assistance are that patients must have a household income below a certain threshold.
No prescribing-information support provided in the supplied label sections.
The household income threshold for Vascepa assistance varies depending on the program.
No prescribing-information support provided in the supplied label sections.
To qualify for Vascepa assistance, patients must meet eligibility criteria that typically include insurance requirements.
No prescribing-information support provided in the supplied label sections.
Insurance requirements for Vascepa assistance include having insurance that covers Vascepa.
No prescribing-information support provided in the supplied label sections.
Insurance requirements for Vascepa assistance may include having inadequate coverage to pay for the medication.
No prescribing-information support provided in the supplied label sections.
To qualify for Vascepa assistance, patients must meet eligibility criteria that typically include medical requirements.
No prescribing-information support provided in the supplied label sections.
Medical requirements for Vascepa assistance include having a diagnosis of severe hypertriglyceridemia or other conditions that require treatment with Vascepa.
No prescribing-information support provided in the supplied label sections.
The Vascepa Patient Assistance Program provides free Vascepa to eligible patients who are uninsured or underinsured.
No prescribing-information support provided in the supplied label sections.
The Vascepa Co-Pay Program offers discounts on Vascepa copays for eligible patients who have insurance that covers the medication.
No prescribing-information support provided in the supplied label sections.
The Vascepa Patient Assistance Foundation provides financial assistance to eligible patients who are struggling to pay for Vascepa.
No prescribing-information support provided in the supplied label sections.
Vascepa assistance can be checked by visiting the manufacturer's website or contacting a healthcare provider.
No prescribing-information support provided in the supplied label sections for assistance-check process; only general info site/phone for more information appears.
Applying for Vascepa assistance requires gathering documents such as proof of income, insurance information, and medical records.
No prescribing-information support provided in the supplied label sections.
Vascepa assistance applications can be submitted online or by mail.
No prescribing-information support provided in the supplied label sections.
Patients will receive a decision on their Vascepa assistance application within a few weeks.
No prescribing-information support provided in the supplied label sections.
Government programs such as Medicaid and Medicare may cover Vascepa for eligible patients.
No prescribing-information support provided in the supplied label sections.
Contradictions
Low
AI Statement
VASCEPA has been shown to determine/reduce the risk of pancreatitis in patients with severe hypertriglyceridemia.
Label Reference
Section 1 INDICATIONS AND USAGE (Limitations of Use): 'The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.'
Low
AI Statement
In pediatric patients, the safety and effectiveness of VASCEPA have been established.
Label Reference
Section 8.4 Pediatric Use: 'Safety and effectiveness in pediatric patients have not been established.'
Low
AI Statement
VASCEPA is not intended to be swallowed whole (may be broken open/crushed/dissolved/chewed).
Label Reference
Section 17 Patient Counseling Information: 'Advise patients to swallow VASCEPA capsules whole. Do not break open, crush, dissolve, or chew VASCEPA.'
Low
AI Statement
Use of VASCEPA in pregnancy is associated with identified fetal/maternal risk (major birth defects, miscarriage, or adverse outcomes) based on available data.
Label Reference
Section 8.1 Pregnancy Risk Summary: 'insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes.'
Important Omissions
For any claims about pancreatitis risk reduction, the label limitation that the effect on pancreatitis risk has not been determined is required for accuracy.
Importance:
Moderate
For any claims about pediatric efficacy/safety, the label statement that safety/effectiveness have not been established is material.
Importance:
Moderate
For any claims about capsule handling, the label instructions to swallow capsules whole (do not break open/crush/dissolve/chew) are material.
Importance:
Moderate
For any claims about pregnancy risk, the label states available data are insufficient to identify a drug-associated risk; asserting identified risk is materially inaccurate.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several contradictions involve potentially actionable label content (capsule swallowing instructions) and population-risk framing (pregnancy/pediatric). While not all claims are label-driven, the contradictory statements increase risk of misinforming use and patient counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Multiple claims are unsupported by the provided label sections and several directly contradict the FDA label (pregnancy risk framing, pediatric safety/effectiveness, capsule handling, and pancreatitis-risk determination).
Suggested Improvement
Limit statements strictly to the provided label sections: correct/remove contradictions and do not assert details about assistance program eligibility/processing/coverage unless supported in the provided prescribing information.